



## Milestone Pharmaceuticals to Present at Upcoming Investor Conferences

November 14, 2019

MONTREAL and CHARLOTTE, N.C., Nov. 14, 2019 /PRNewswire/ -- Milestone Pharmaceuticals Inc. (Nasdaq: MIST) today announced that Joseph G. Oliveto, President and Chief Executive Officer, will present at the following investor conferences:

- The Jefferies 2019 London Healthcare Conference on Thursday, November 21, 2019 at 3:20 p.m. Greenwich Mean Time (10:20 a.m. Eastern Time)
- The Piper Jaffray 31<sup>st</sup> Annual Healthcare Conference in New York on Wednesday, December 4, 2019 at 3:30 p.m. Eastern Time

A live webcast of each presentation can be accessed in the News & Events section of Milestone's website at [www.milestonepharma.com](http://www.milestonepharma.com). An archived replay of each webcast will be available on the same website for approximately 30 days following the presentation.

### About Milestone Pharmaceuticals

Milestone is a Phase 3 clinical-stage biopharmaceutical company dedicated to developing and commercializing the investigational new drug etripamil for the treatment of cardiovascular indications. Etripamil is a novel, potent and short-acting calcium channel blocker designed by Milestone and being developed as a rapid-onset nasal spray to be administered by the patient to terminate episodes of PSVT as they occur. Milestone is actively recruiting patients for a Phase 3 clinical trial of etripamil for the treatment of PSVT. Top-line data from the phase 3 pivotal efficacy trial (NODE-301) is expected in the middle of the first half of 2020.

### Contact:

David Pitts  
Argot Partners  
212-600-1902  
[david@argotpartners.com](mailto:david@argotpartners.com)



 View original content to download multimedia: <http://www.prnewswire.com/news-releases/milestone-pharmaceuticals-to-present-at-upcoming-investor-conferences-300957945.html>

SOURCE Milestone Pharmaceuticals, Inc.